Cansino Biologics Valuation
| 688185 Stock | 55.11 1.99 3.49% |
At this time, the firm appears to be overvalued. Cansino Biologics shows a prevailing Real Value of USD49.93 per share. The current price of the firm is USD55.11. Our model approximates the value of Cansino Biologics from analyzing the firm fundamentals such as Return On Equity of -0.14, current valuation of 8.41 B, and Profit Margin of (0.96) % as well as examining its technical indicators and probability of bankruptcy.
Price Book 2.6953 | Enterprise Value 8.4 B | Enterprise Value Ebitda (3.94) | Price Sales 13.0177 | Enterprise Value Revenue 13.8024 |
Overvalued
Today
Please note that Cansino Biologics' price fluctuation is very steady at this time. Calculation of the real value of Cansino Biologics is based on 3 months time horizon. Increasing Cansino Biologics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cansino Biologics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cansino Stock. However, Cansino Biologics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 55.11 | Real 49.93 | Hype 55.11 | Naive 54.13 |
The real value of Cansino Stock, also known as its intrinsic value, is the underlying worth of Cansino Biologics Company, which is reflected in its stock price. It is based on Cansino Biologics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cansino Biologics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cansino Biologics helps investors to forecast how Cansino stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cansino Biologics more accurately as focusing exclusively on Cansino Biologics' fundamentals will not take into account other important factors: Cansino Biologics Cash |
|
Cansino Biologics Total Value Analysis
Cansino Biologics is presently estimated to have takeover price of 8.41 B with market capitalization of 9.74 B, debt of 1.39 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cansino Biologics fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.41 B | 9.74 B | 1.39 B |
Cansino Biologics Investor Information
About 62.0% of the company shares are owned by insiders or employees . The book value of Cansino Biologics was presently reported as 20.58. The company recorded a loss per share of 3.52. Cansino Biologics last dividend was issued on the 23rd of August 2022. Based on the key indicators related to Cansino Biologics' liquidity, profitability, solvency, and operating efficiency, Cansino Biologics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Cansino Biologics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cansino Biologics has an asset utilization ratio of 3.7 percent. This suggests that the Company is making USD0.037 for each dollar of assets. An increasing asset utilization means that Cansino Biologics is more efficient with each dollar of assets it utilizes for everyday operations.Cansino Biologics Ownership Allocation
Cansino Biologics holds a total of 114.78 Million outstanding shares. Cansino Biologics shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 61.93 percent of Cansino Biologics outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cansino Biologics Profitability Analysis
The company reported the revenue of 345.18 M. Net Loss for the year was (1.45 B) with loss before overhead, payroll, taxes, and interest of (25.87 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cansino Biologics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cansino Biologics and how it compares across the competition.
About Cansino Biologics Valuation
The stock valuation mechanism determines Cansino Biologics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Cansino Biologics. We calculate exposure to Cansino Biologics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cansino Biologics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -1 B | -957.1 M |
Complementary Tools for Cansino Stock analysis
When running Cansino Biologics' price analysis, check to measure Cansino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansino Biologics is operating at the current time. Most of Cansino Biologics' value examination focuses on studying past and present price action to predict the probability of Cansino Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cansino Biologics' price. Additionally, you may evaluate how the addition of Cansino Biologics to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |